MOESM1 of Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3

Aldo Scarpa (242345); Alessandra Fiore (7402703); Carmine Carbone (7402730); Claudio Bassi (306480); Cristina Anselmi (7402718); Francesca Hofer (7402721); Francesco Sanctis (7402715); Geny Piro (7402727); Laura Pinton (6409133); Luciano Cascione (280104); Ornella Poffe (374339); Rita Lawlor (6468023); Roberto Salvia (3113151); Rosalba Giugno (46523); Rosalinda Trovato (7402700); Salvatore Paiella (7402712); Samantha Solito (6409142); Sara Sartori (7402706); Silvia Sartoris (7402724); Stefania CanĂ¨ (7402736); Stefano Ugel (7402733); Susanna Mandruzzato (6409154); Vincenzo Bronte (234424); Vincenzo Corbo (242342)

journal article text

MOESM1 of Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3

Abstract

Additional file 1. Supplementary methods. Figure S1. Gating strategy to identify tumor-infiltrating leukocytes. Figure S2. Immune characterization of PDAC tumor microenvironment. Figure S3. Gating strategy to identify circulating MDSCs in fresh whole blood. Figure S4. Prognostic potential role of MDSCs in PDAC patients. Figure S5. Gene signature of CD14+ cells isolated from PDAC patients. Figure S6. Enumeration of circulating CD14+ARG1+ cells in PDAC patients

Similar works

Full text

Available Versions

The Francis Crick Institute

oai:figshare.com:article/98775...

Last time updated on 06/04/2020